2024
1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
Di Federico A, Chen M, Pagliaro A, Ogliari F, Stockhammer P, Aldea M, Grant M, De Giglio A, Alessi J, Pecci F, Gelsomino F, Negrao M, Ferrara R, Awad M, Riely G, Ardizzoni A, Planchard D, Offin M, Johnson B, Ricciuti B. 1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer. Annals Of Oncology 2024, 35: s826-s827. DOI: 10.1016/j.annonc.2024.08.1356.Peer-Reviewed Original Research
2023
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
Grant M, Aredo J, Starrett J, Stockhammer P, van Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.Peer-Reviewed Original ResearchConceptsProgression-free survivalNon-small cell lung cancerInferior progression-free survivalMulticenter retrospective cohortEfficacy of osimertinibMulti-institutional cohortCell lung cancerExon 19 deletion mutationUncommon EGFRRetrospective cohortClinical outcomesClinical efficacyLung cancerOsimertinib efficacyEGFR mutationsPreclinical modelsEx19delPatientsAACR Genie databaseLater linesOsimertinibMutant cohortFirst lineCohortEfficacy
2019
Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma
Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer 2019, 139: 124-132. PMID: 31778960, DOI: 10.1016/j.lungcan.2019.11.013.Peer-Reviewed Original ResearchConceptsMalignant pleural mesotheliomaNon-malignant pleural diseasePleural effusionMPM patientsPleural mesotheliomaPrognostic stratificationNon-epithelioid malignant pleural mesotheliomaStage IV lung cancerEpithelioid malignant pleural mesotheliomaInferior overall survivalTGF-β levelsLevels of TGFLung cancer patientsChest CT scanOverall survivalSMRP levelsClinicopathological characteristicsDismal prognosisPleural diseaseTumor loadAggressive malignancyDisease stageCancer patientsLung cancerPrimary diagnosisImplementation of an experimental isolated lung perfusion model on surgically resected human lobes
Slama A, Raber C, Hedderich C, Stockhammer P, Hegedüs B, Koch A, Theegarten D, Ploenes T, Aigner C. Implementation of an experimental isolated lung perfusion model on surgically resected human lobes. Scientific Reports 2019, 9: 12193. PMID: 31434960, PMCID: PMC6704181, DOI: 10.1038/s41598-019-48719-8.Peer-Reviewed Original ResearchConceptsIsolated lung perfusionAnatomic pulmonary lobectomyLung perfusion modelExperimental lung researchDonor lungsIschemic timeMedian durationVariety of pathologiesPulmonary lobectomyLung perfusionMechanical ventilationArterial ligationLung cancerMetabolic parametersNormothermic conditionsRespiratory parametersPerfusion modelTreatment effectsLobePerfusionCancer researchLung researchVentilationPhysiological settingsAnimal organs